N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=92 Respiratory Dysregulation and Breathing Training in Anxious Outpatients
Anxiety
Primary: Episodic Anxiety Scale — 8.1; 9.0; 14.3 units on a scale
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=186 Evaluation of a "Fast Track" Respiratory Therapy Clinic for Patients With Suspected Severe Sleep-Disordered Breathing
Sleep Disordered Breathing
Primary: Adherence to Positive Airway Pressure (PAP) Therapy — 4; 3.5 hours per night
Early Phase 1 N=63 Respiratory and Autonomic Plasticity Following Intermittent Hypoxia
Sleep Apnea Syndromes
Primary: Ventilation (Aim 1) — 1.19; 1.14; 1.35; 1.16 fraction of baseline — p=0.001
N/A N=63 Treatment of Sleep-disordered Breathing in Patients With SCI
Spinal Cord Injury · Sleep-disordered Breathing · Spinal Cord Disease
Primary: PAP Adherence — 22.03; 18.54 nights
N/A N=10 Respiratory Capacity and Swallowing Function in Spinal Disorders: A Pilot Study
Spinal Cord Injuries · Deglutition Disorders
Primary: Number of Participants Displaying Unsafe Swallowing — 0; 0; 0; 0 Participants
N/A N=74 Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury
Obstructive Sleep Apnea · Hypercapnia · Spinal Cord Injury
Primary: Prevalence of Sleep-disordered Breathing in Spinal Cord-injured Adults — 40; 23; 11 participants
N/A N=317 Obstructive Sleep Apnea in World Trade Center Responders
Obstructive Sleep Apnea
Primary: Adherence to CPAP Pre-crossover — 1; 0.89 Hours/night
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 3 N=42 Expiratory Muscle Training for Persons With Neurodegenerative Disease
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
N/A N=21 Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease
Neuromuscular Diseases
Primary: Change From Baseline Vital Capacity at One Year. — 33.33; -7.41 percentage of Change of vital capacity — p=<0.001
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
N/A N=29 Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
Amyotrophic Lateral Sclerosis (ALS) · Neuromuscular Diseases
Primary: Percent Change in Maximal Inspiratory Pressure (MIP) — 0.3; -3.1; -4.8; -5.0 percentage change in MIP from baseline
N/A N=60 Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Lung Diseases · Medication Compliance
Primary: Forced Oscillation Technique (FOT) Measures — 4.4; 3.7; 1.0; 0.6 resonant frequency
Phase 2 N=30 High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer
Advanced Cancers
Primary: Number of Participants Completing Study Intervention — 7; 10; 3; 5 Participants
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
N/A N=6 Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)
Healthy Adult Volunteers
Primary: Change in End-expiratory Lung Volume — -144; 103 mL
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=25 Respiratory Strength Training in Cardiac Surgical Patients
Cardiovascular Diseases · Thoracic Diseases · Surgery
Primary: Adherence to Respiratory Strength Training — 35750 Repetitions
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
N/A N=15 Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions — 6.3; 17.5; 11.4; 5.6 minutes — p=<0.05
N/A N=20 Respiratory Muscle Strength Training in Presbyphonia
Presbylarynx
Primary: Post-Treatment Mean in Voice Handicap Index Score — 15.00; 15.75; 18.50 score on a scale — p=0.041
Phase 2 N=44 Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events